Your browser doesn't support javascript.
loading
Practical considerations in epilepsy neurostimulation.
Simpson, Hugh D; Schulze-Bonhage, Andreas; Cascino, Gregory D; Fisher, Robert S; Jobst, Barbara C; Sperling, Michael R; Lundstrom, Brian N.
Afiliación
  • Simpson HD; Division of Epilepsy, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Schulze-Bonhage A; Epilepsy Center, University Medical Center-University of Freiburg, Freiburg, Germany.
  • Cascino GD; Division of Epilepsy, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Fisher RS; Department of Neurology, Stanford Neuroscience Health Center, Palo Alto, California, USA.
  • Jobst BC; Department of Neurology, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, USA.
  • Sperling MR; Division of Epilepsy, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Lundstrom BN; Division of Epilepsy, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Epilepsia ; 63(10): 2445-2460, 2022 10.
Article en En | MEDLINE | ID: mdl-35700144
Neuromodulation is a key therapeutic tool for clinicians managing patients with drug-resistant epilepsy. Multiple devices are available with long-term follow-up and real-world experience. The aim of this review is to give a practical summary of available neuromodulation techniques to guide the selection of modalities, focusing on patient selection for devices, common approaches and techniques for initiation of programming, and outpatient management issues. Vagus nerve stimulation (VNS), deep brain stimulation of the anterior nucleus of the thalamus (DBS-ANT), and responsive neurostimulation (RNS) are all supported by randomized controlled trials that show safety and a significant impact on seizure reduction, as well as a suggestion of reduction in the risk of sudden unexplained death in epilepsy (SUDEP). Significant seizure reductions are observed after 3 months for DBS, RNS, and VNS in randomized controlled trials, and efficacy appears to improve with time out to 7 to 10 years of follow-up for all modalities, albeit in uncontrolled follow-up or retrospective studies. A significant number of patients experience seizure-free intervals of 6 months or more with all three modalities. Number and location of epileptogenic foci are important factors affecting efficacy, and together with comorbidities such as severe mood or sleep disorders, may influence the choice of modality. Programming has evolved-DBS is typically initiated at lower current/voltage than used in the pivotal trial, whereas target charge density is lower with RNS, however generalizable optimal parameters are yet to be defined. Noninvasive brain stimulation is an emerging stimulation modality, although it is currently not used widely. In summary, clinical practice has evolved from those established in pivotal trials. Guidance is now available for clinicians who wish to expand their approach, and choice of neuromodulation technique may be tailored to individual patients based on their epilepsy characteristics, risk tolerance, and preferences.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Núcleos Talámicos Anteriores / Estimulación Encefálica Profunda / Epilepsia / Estimulación del Nervio Vago / Epilepsia Refractaria Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Epilepsia Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Núcleos Talámicos Anteriores / Estimulación Encefálica Profunda / Epilepsia / Estimulación del Nervio Vago / Epilepsia Refractaria Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Epilepsia Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos